Nippon Chemiphar Past Earnings Performance
Past criteria checks 0/6
Nippon Chemiphar's earnings have been declining at an average annual rate of -25.7%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 1.1% per year.
Key information
-25.7%
Earnings growth rate
-25.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | -1.1% |
| Return on equity | -0.7% |
| Net Margin | -0.4% |
| Next Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nippon Chemiphar makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 31,207 | -133 | 6,041 | 2,325 |
| 31 Mar 24 | 30,748 | -180 | 5,907 | 2,325 |
| 31 Dec 23 | 30,613 | -241 | 5,731 | 2,419 |
| 30 Sep 23 | 30,159 | -526 | 5,844 | 2,419 |
| 30 Jun 23 | 30,671 | -235 | 5,913 | 2,419 |
| 31 Mar 23 | 31,559 | 339 | 6,006 | 2,419 |
| 31 Dec 22 | 31,794 | 432 | 6,027 | 2,392 |
| 30 Sep 22 | 33,168 | 1,368 | 5,846 | 2,392 |
| 30 Jun 22 | 33,356 | 1,366 | 5,835 | 2,392 |
| 31 Mar 22 | 32,506 | 700 | 5,856 | 2,392 |
| 31 Dec 21 | 32,656 | 1,112 | 6,570 | 1,998 |
| 30 Sep 21 | 32,284 | 980 | 7,409 | 1,998 |
| 30 Jun 21 | 31,920 | 463 | 8,363 | 1,998 |
| 31 Mar 21 | 31,541 | 495 | 8,881 | 1,998 |
| 31 Dec 20 | 31,102 | 104 | 9,091 | 2,173 |
| 30 Sep 20 | 30,491 | -147 | 9,335 | 2,173 |
| 30 Jun 20 | 30,648 | 35 | 9,567 | 2,173 |
| 31 Mar 20 | 31,756 | 436 | 10,017 | 2,173 |
| 31 Dec 19 | 32,771 | 717 | 10,440 | 2,066 |
| 30 Sep 19 | 33,642 | 716 | 10,771 | 2,066 |
| 30 Jun 19 | 33,940 | 1,016 | 10,828 | 2,066 |
| 31 Mar 19 | 34,182 | 881 | 10,997 | 2,066 |
| 31 Dec 18 | 33,776 | 707 | 10,928 | 2,280 |
| 30 Sep 18 | 34,456 | 921 | 11,180 | 2,280 |
| 30 Jun 18 | 35,136 | 1,037 | 11,468 | 2,280 |
| 31 Mar 18 | 35,331 | 1,160 | 11,667 | 2,280 |
| 31 Dec 17 | 36,035 | 1,650 | 11,941 | 1,984 |
| 30 Sep 17 | 35,686 | 1,962 | 11,783 | 1,984 |
| 30 Jun 17 | 35,625 | 2,000 | 11,602 | 1,984 |
| 31 Mar 17 | 35,689 | 2,054 | 11,419 | 1,984 |
| 31 Dec 16 | 35,574 | 2,038 | 11,487 | 1,889 |
| 30 Sep 16 | 35,689 | 1,906 | 11,591 | 1,889 |
| 30 Jun 16 | 35,778 | 2,009 | 11,583 | 1,889 |
| 31 Mar 16 | 35,602 | 1,962 | 11,764 | 1,889 |
| 31 Dec 15 | 34,907 | 1,720 | 11,820 | 1,755 |
| 30 Sep 15 | 35,074 | 1,732 | 11,869 | 1,755 |
| 30 Jun 15 | 34,937 | 1,687 | 11,801 | 1,755 |
| 31 Mar 15 | 35,119 | 1,900 | 11,725 | 1,755 |
| 31 Dec 14 | 34,721 | 1,940 | 11,837 | 1,668 |
| 30 Sep 14 | 33,920 | 1,898 | 11,862 | 1,668 |
| 30 Jun 14 | 33,008 | 1,952 | 11,800 | 1,668 |
| 31 Mar 14 | 31,893 | 1,887 | 11,769 | 1,668 |
| 31 Dec 13 | 31,342 | 1,898 | 11,429 | 1,936 |
| 30 Sep 13 | 30,780 | 1,816 | 11,309 | 1,936 |
Quality Earnings: 4539 is currently unprofitable.
Growing Profit Margin: 4539 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4539 is unprofitable, and losses have increased over the past 5 years at a rate of 25.7% per year.
Accelerating Growth: Unable to compare 4539's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4539 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).
Return on Equity
High ROE: 4539 has a negative Return on Equity (-0.72%), as it is currently unprofitable.